Grant: Project Grant
Queen's University (Kingston, Ontario)
$1,128,374.00
Monitoring the response to Lung Cancer Immunotherapy using an mDETECT Liquid Biopsy
FY 2025-26
Summary
Lung cancer is responsible for the greatest number of cancer deaths because it is often
diagnosed late and the treatments for it are not that effective. A new type of treatment
(immunotherapy) that uses the person's own immune system to kill cancer cells is becoming
increasingly popular because it has worked really well in some patients with advanced
disease to completely make their cancer disappear and some have even been cured. The
problem with this treatment is that it is very difficult to tell which patients will respond and
which will not, as well as not knowing how or when to change treatments to make them work
better. We have developed a blood test that looks directly at how much cancer is present in a patient and changes in the amount of cancer can show if the treatment is working or not. This test can give results very quickly, within weeks of starting a treatment, instead of the 3 months it now takes using CT scans. With this new tool we will be able to help doctors optimize these treatments, making them more effective in a greater number of patients. For patients that do not respond initially, extra drugs and even radiation can be added in to help boost the effectiveness of the treatment. This will allow for the tailoring of treatments to individual patients based on their ongoing response, hopefully leading to longer and healthier lives.
Department
Program
Project Grant
Location
Ontario, Canada
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
566657
Name
Mueller Christopher R
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Commercialization
Projecttitle
Monitoring the response to Lung Cancer Immunotherapy using an mDETECT Liquid Biopsy
Programtype2
Operating Grants
Orgnameinp2
Queen's University (Kingston, Ontario)
Cihramount2
$1,128,374
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Chemotherapy; Immunotherapy; Liquid Biopsy; Lung Cancer; Response Directed Therapy; Selection
Abstract
Lung cancer is responsible for the greatest number of cancer deaths because it is often
diagnosed late and the treatments for it are not that effective. A new type of treatment
(immunotherapy) that uses the person's own immune system to kill cancer cells is becoming
increasingly popular because it has worked really well in some patients with advanced
disease to completely make their cancer disappear and some have even been cured. The
problem with this treatment is that it is very difficult to tell which patients will respond and
which will not, as well as not knowing how or when to change treatments to make them work
better. We have developed a blood test that looks directly at how much cancer is present in a patient and changes in the amount of cancer can show if the treatment is working or not. This test can give results very quickly, within weeks of starting a treatment, instead of the 3 months it now takes using CT scans. With this new tool we will be able to help doctors optimize these treatments, making them more effective in a greater number of patients. For patients that do not respond initially, extra drugs and even radiation can be added in to help boost the effectiveness of the treatment. This will allow for the tailoring of treatments to individual patients based on their ongoing response, hopefully leading to longer and healthier lives.
Competitiondate
202603
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Mueller, Christopher R
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $1,128,374~ $0~